Should You Buy Rocket Lab While It's Below $27?

Rocket Lab's stock has rebounded after positive press releases regarding contracts with the U.S. Air Force, NASA, and iQPS, as well as a successful launch and recovery for Varda Space Industries, yet the author suggests caution, noting the current valuation is high relative to present earnings and sales. While future projections show promise, the stock's price is heavily influenced by momentum and upcoming catalysts like the Neutron rocket launch; a potential launch delay could create a more attractive entry point for long-term investors.

Analysis

Rocket Lab (RKLB) has demonstrated operational momentum with several key contract wins, including with the U.S. Air Force Research Laboratory for experimental cargo transport, NASA for the Aspera spacecraft launch, Japan's iQPS for a SAR launch, and Varda Space Industries for orbital pharmaceuticals. This news flow has propelled the stock 9% above its price prior to its recent earnings miss, though it remains 20% below its January intraday high. Despite these positive developments and long-term analyst forecasts projecting $3.5 billion in revenue and $1.1 billion in GAAP profit within five years (implying a forward P/E of approximately 11 on its current $12 billion market cap), the immediate financial picture is less clear. The company currently has negative earnings, and its valuation at over 27 times trailing sales is notably high. Analyst consensus has also seen revisions, with a previously expected profit in 2025 now pushed out, and a $193 million loss forecasted for the current year, indicating significant uncertainty in achieving long-term targets. The stock's behavior is characteristic of a momentum play, reacting sharply to headlines, with the anticipated Neutron rocket launch (potentially as early as July) largely factored into the current price.

Key Decisions for Investors

• Investors should exercise caution due to Rocket Lab's elevated valuation, specifically its price-to-sales ratio exceeding 27, and the stock's current dependence on news flow rather than positive earnings.
• A patient approach may be warranted, watching for potential price pullbacks, possibly driven by any delays in the Neutron rocket's inaugural launch, which could present a more favorable entry point for long-term investors without necessarily impairing the company's fundamental outlook.
• Closely monitor milestones related to the Neutron rocket's development and launch timeline, as well as future earnings releases, for tangible progress towards profitability and validation of long-term growth projections.